/ Print /

Policy & Regulation Strategy

Opinion: Cost transparency improves collections and boosts satisfactionConsider providing cost estimates prior to rendering care to increase collections, patient satisfaction.
How Americans really feel about the AHCAA new Kaiser poll has surprising results and three important findings.
AHCA next steps: 4 things MCOs should knowWhat are the next steps for the bill, and how likely is it that it will become law? Here’s are four things MCOs should know.
Opinion: Biggest problems with single-payer ‘Medicare-for-all’Our policy analyst explains why he believes single payer Medicare-for-all is a pipe dream.
Top ACA provisions employers want to keepA Willis Towers Watson survey finds that employers see enhancing the employee experience in healthcare as key to boosting health engagement.
Congress considering ‘invisible’ high-risk poolsOur policy analyst explains the concept of invisible high-risk pools, and explains how they might affect health reform.
Four reasons GOP ACA replacement failed without a voteWhat exactly did House representatives on both sides of the aisle dislike about the AHCA? Here’s a look at what MCOs should know.
Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
State medical marijuana laws continue to expandMedical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.